The US ophthalmic disease venture Acucela has floated on the Mothers high-tech bourse of the Tokyo Stock Exchange, raising JPY15.15bn (around $148m) to progress its lead drug emixustat and other projects.
written on 13.02.2014
Acucela surges after $148m Japan IPO
